Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Baudax Bio, Inc. (BXRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Investor presentation |
| 07/17/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Investor presentation |
| 03/03/2023 |
8-K
| Investor presentation |
| 01/09/2023 |
8-K
| Investor presentation |
| 08/23/2022 |
8-K
| Investor presentation |
| 04/20/2022 |
8-K
| Investor presentation |
| 01/04/2022 |
8-K
| Investor presentation |
| 11/04/2021 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"BAUDAX BIO, INC. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 14,772 $ 30,342 Short-term investments 10,150 — Accounts receivable, net 422 51 Inventory 4,310 2,978 Prepaid expenses and other current assets 1,484 3,346 Total current assets 31,138 36,717 Property, plant and equipment, net 4,933 5,052 Intangible assets, net 22,322 24,254 Goodwill 2,127 2,127 Other long-term assets 979 583 Total assets $ 61,499 $ 68,733 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 1,819 $ 3,653 Accrued expenses and other current liabilities 4,568 5,326 Current portion of long-term debt, net 1,389 683 Current portion of contingent consideration 6,666 8,467 Total current liabilities 14,442 18,129 Long-term debt, net 6,913 8,469 Long-term portion...",
"9 CA, AZ, AR, AL" |
|
| 08/05/2021 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"BAUDAX BIO, INC. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 25,412 $ 30,342 Short-term investments 12,147 — Accounts receivable, net 219 51 Inventory, net 3,558 2,978 Prepaid expenses and other current assets 1,945 3,346 Total current assets 43,281 36,717 Property, plant and equipment, net 4,979 5,052 Intangible assets, net 22,966 24,254 Goodwill 2,127 2,127 Other long-term assets 455 583 Total assets $ 73,808 $ 68,733 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 2,085 $ 3,653 Accrued expenses and other current liabilities 5,084 5,326 Current portion of long-term debt, net 555 683 Current portion of contingent consideration 6,098 8,467 Total current liabilities 13,822 18,129 Long-term debt, net 7,518 8,469 Long-term port...",
"Baudax Bio Q2 Update August 5, 2021 Forward Looking Statements This" |
|
| 05/05/2021 |
8-K
| Quarterly results |
| 04/07/2021 |
8-K
| Quarterly results |
| 02/16/2021 |
8-K
| Quarterly results |
| 01/05/2021 |
8-K
| Quarterly results |
| 09/22/2020 |
8-K
| Investor presentation |
| 07/20/2020 |
8-K
| Quarterly results |
| 02/21/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
|
|